Blue Trust’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,634
Closed -$13.7K – 2527
2026
Q2
$13.7K Sell
1,634
-35
-2% -$319 ﹤0.01% 1771
2026
Q1
$15K Sell
1,669
-2,600
-61% -$41K ﹤0.01% 1727
2025
Q4
$77.9K Buy
4,269
+2,477
+138% +$41.7K ﹤0.01% 1174
2025
Q3
$26.3K Sell
1,792
-970
-35% -$16.6K ﹤0.01% 1597
2025
Q2
$50.3K Buy
2,762
+964
+54% +$19.7K ﹤0.01% 1454
2025
Q1
$35.7K Buy
+1,798
New +$31.1K ﹤0.01% 1509

Other funds holding ADMA

Blue Trust's ADMA Position: Q3 2026 in Review

Blue Trust sold out of ADMA Biologics (ADMA) in Q3 2026, closing a stake of 1,634 shares — an estimated $13.7K sold.

Blue Trust first reported a position in ADMA in Q1 2025 and held it in 6 quarters. The position peaked at $77.9K in Q4 2025. 266 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Blue Trust reported no remaining ADMA Biologics position as of Q3 2026 after selling out during the quarter.
  • Blue Trust sold 1,634 ADMA Biologics shares in Q3 2026, an estimated $13.7K.
  • Blue Trust first reported a position in ADMA Biologics in Q1 2025 and held it in 6 quarters.
  • Blue Trust's ADMA Biologics position peaked at $77.9K in Q4 2025.
  • 266 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.